NCT03024437 2025-03-20
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Phase 1/2 Terminated
Clinical Trials
12 trialsNCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00113217 2020-09-23
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00853021 2019-06-05
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00934440 2017-06-14
5-AZ
University of Kansas Medical Center
Phase 1/2 Terminated
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT00601926 2015-06-15
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00455975 2014-12-22
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00323739 2013-07-26
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed